<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JNCI Cancer Spectr</journal-id><journal-id journal-id-type="iso-abbrev">JNCI Cancer Spectr</journal-id><journal-id journal-id-type="pmc-domain-id">3695</journal-id><journal-id journal-id-type="pmc-domain">jncicanspec</journal-id><journal-id journal-id-type="publisher-id">jncics</journal-id><journal-title-group><journal-title>JNCI Cancer Spectrum</journal-title></journal-title-group><issn pub-type="epub">2515-5091</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10880071</article-id><article-id pub-id-type="pmcid-ver">PMC10880071.1</article-id><article-id pub-id-type="pmcaid">10880071</article-id><article-id pub-id-type="pmcaiid">10880071</article-id><article-id pub-id-type="pmid">38268502</article-id><article-id pub-id-type="doi">10.1093/jncics/pkae003</article-id><article-id pub-id-type="publisher-id">pkae003</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject></subj-group></article-categories><title-group><article-title>Trajectories and predictors of high-occurrence pain flares in ambulatory cancer patients on opioids</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5866-8279</contrib-id><name name-style="western"><surname>Meghani</surname><given-names initials="SH">Salimah H</given-names></name><degrees>PhD, MBE</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Department of Biobehavioral Health Sciences; NewCourtland Center for Transitions and Health, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff><aff>
<institution>Abramson Cancer Center, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff><aff>
<institution>Leonard Davis Institute of Health Economics, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff><xref rid="pkae003-cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Quinn</surname><given-names initials="R">Ryan</given-names></name><degrees>MPH</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Department of Biobehavioral Health Sciences; NewCourtland Center for Transitions and Health, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Robinson</surname><given-names initials="A">Andrew</given-names></name><degrees>BA</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Department of Biobehavioral Health Sciences; NewCourtland Center for Transitions and Health, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chittams</surname><given-names initials="J">Jesse</given-names></name><degrees>MA</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Department of Biobehavioral Health Sciences; NewCourtland Center for Transitions and Health, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vapiwala</surname><given-names initials="N">Neha</given-names></name><degrees>MD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Abramson Cancer Center, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Naylor</surname><given-names initials="M">Mary</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Department of Biobehavioral Health Sciences; NewCourtland Center for Transitions and Health, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff><aff>
<institution>Leonard Davis Institute of Health Economics, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6793-6474</contrib-id><name name-style="western"><surname>Cheatle</surname><given-names initials="M">Martin</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Perelman School of Medicine, University of Pennsylvania</institution>, Philadelphia, PA, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Knafl</surname><given-names initials="GJ">George J</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>School of Nursing, University of North Carolina at Chapel Hill</institution>, Chapel Hill, NC, <country country="US">USA</country></aff></contrib></contrib-group><author-notes><corresp id="pkae003-cor1"><bold>Correspondence to:</bold> Salimah H. Meghani, PhD, MBE, FAAN, University of Pennsylvania, 418 Curie Blvd, Fagin Hall 337, Philadelphia, PA 19104, USA (e-mail: <email>salimahm@nursing.upenn.edu</email>).</corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-01-24"><day>24</day><month>1</month><year>2024</year></pub-date><volume>8</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">452444</issue-id><elocation-id>pkae003</elocation-id><history><date date-type="received"><day>15</day><month>12</month><year>2023</year></date><date date-type="rev-recd"><day>11</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2024</year></date><date date-type="corrected-typeset"><day>20</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>21</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-22 00:25:10.423"><day>22</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pkae003.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pkae003.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Pain flares have a substantive impact on the quality of life and well-being of patients with cancer. We identified longitudinal trajectories (clusters) of cancer pain flares in ambulatory patients and sociodemographic and clinical predictors of these trajectories.</p></sec><sec id="s2"><title>Methods</title><p>In a prospective cohort study using ecological momentary assessment (mEMA), we collected patient-reported daily pain flare ratings data over 5&#8201;months and identified predictors and correlates using validated measures.</p></sec><sec id="s3"><title>Results</title><p>The mean age of the sample (N&#8201;=&#8201;270) was 60.9&#8201;years (SD&#8201;=&#8201;11.2), 64.8% were female, and 32.6% self-identified as African American. Four pain flare clusters were identified. The &#8220;high-occurrence&#8221; cluster (23% of patients) experienced 5.5 (SD = 5.47) daily flares, whereas low-moderate clusters (77%) reported 2.4 (SD = 2.74) daily flares (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.000). Those in the high-occurrence cluster reported higher pain scores (<italic toggle="yes">P</italic>&#8201;=&#8201;.000), increased pain-related interference (<italic toggle="yes">P</italic>&#8201;=&#8201;.000), depressive symptoms (<italic toggle="yes">P</italic>&#8201;=&#8201;.023), lower quality of life (<italic toggle="yes">P</italic>&#8201;=&#8201;.001), and reduced pain self-efficacy (<italic toggle="yes">P</italic>&#8201;=&#8201;.006). Notably, 67.2% of those prescribed opioids as needed (PRN only) were in the high-occurrence pain flare cluster, compared with 27.9% with PRN and around-the-clock opioid prescriptions (<italic toggle="yes">P</italic>&#8201;=&#8201;.024). Individual predictors of high-occurrence pain flares were income below $30&#8202;000, unemployment, being African American, lower education level, Medicaid insurance, current opioid misuse (COMM), baseline inpatient hospital stay duration, and PRN-only opioid regimen. In the multiple predictor model, lower education level, unemployment, COMM score, extended inpatient duration, and PRN-only opioid regimen remained significant.</p></sec><sec id="s4"><title>Conclusion</title><p>In ambulatory patients with cancer, high occurrence of pain flares may be mitigated by attention to opioid prescription factors and addressing social determinants of health needs of underserved patients.</p></sec></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Cancer pain has a profoundly negative impact on patients&#8217; daily lives and function (<xref rid="pkae003-B1" ref-type="bibr">1</xref>,<xref rid="pkae003-B2" ref-type="bibr">2</xref>). Especially devastating are episodic spikes of cancer pain appearing with a greater intensity (<xref rid="pkae003-B3" ref-type="bibr">3</xref>,<xref rid="pkae003-B4" ref-type="bibr">4</xref>). Unfortunately, this recurrent worsening pain is highly prevalent in cancer patients, with 40% to 81% of ambulatory patients experiencing several episodes of intensified pain daily (<xref rid="pkae003-B5" ref-type="bibr">5-8</xref>). This phenomenon is characterized by a rapid onset to peak intensity (within minutes), with sharp or intense pain lasting&#160;up to an hour (<xref rid="pkae003-B9" ref-type="bibr">9</xref>).</p><p>The phenomenon of acute intensification of cancer pain has been described with many labels in the literature, including breakthrough cancer pain (BTcP) or breakthrough pain (BTP), episodic pain, transient pain, pain exacerbation, intermittent pain, acute-on-chronic pain, spike pain, and pain flares (<xref rid="pkae003-B3" ref-type="bibr">3</xref>,<xref rid="pkae003-B6" ref-type="bibr">6</xref>,<xref rid="pkae003-B10" ref-type="bibr">10-12</xref>). For example, the National Cancer Institute (NCI) defines pain flares interchangeably with BTcP, a definition influenced by the seminal work of Portenoy and Hagen (<xref rid="pkae003-B13" ref-type="bibr">13</xref>). Despite conceptual overlap, as well as similarities in its episodic nature, acute intensification, and rapid onset, BTcP typically occurs against a backdrop of relatively controlled and stable baseline pain and analgesia (<xref rid="pkae003-B3" ref-type="bibr">3</xref>,<xref rid="pkae003-B13" ref-type="bibr">13</xref>), whereas pain flares may also occur in the context of poorly controlled baseline pain or unstable regimen of analgesia (<xref rid="pkae003-B3" ref-type="bibr">3</xref>).</p><p>On the basis of accumulated research, poorly controlled cancer pain is common in oncology patients, especially among racial and ethnic minorities and socially vulnerable groups (<xref rid="pkae003-B14" ref-type="bibr">14-19</xref>) who experience both higher background pain levels (<xref rid="pkae003-B16" ref-type="bibr">16</xref>,<xref rid="pkae003-B18" ref-type="bibr">18</xref>,<xref rid="pkae003-B20" ref-type="bibr">20</xref>) and different or inferior cancer pain management strategies (<xref rid="pkae003-B16" ref-type="bibr">16</xref>,<xref rid="pkae003-B18" ref-type="bibr">18</xref>,<xref rid="pkae003-B21" ref-type="bibr">21</xref>,<xref rid="pkae003-B22" ref-type="bibr">22</xref>). Importantly, in the context of an ongoing opioid crisis, the approach to around-the-clock (ATC) analgesic coverage also has changed in recent years. Between 2013 and 2017, opioid prescriptions by oncologists decreased significantly, in line with downward trends observed among non-oncologists (<xref rid="pkae003-B23" ref-type="bibr">23</xref>,<xref rid="pkae003-B24" ref-type="bibr">24</xref>) and partly attributed to a notable 28.5% decline in long-acting (LA) opioid prescriptions used for ATC pain management (<xref rid="pkae003-B23" ref-type="bibr">23</xref>). These changes also align with stricter opioid regulations and changing attitudes among oncologists toward their use (<xref rid="pkae003-B24" ref-type="bibr">24</xref>,<xref rid="pkae003-B25" ref-type="bibr">25</xref>).</p><p>In 2016, North America represented the region most dramatically impacted by the opioid crisis, with a rate 3 times higher than the global average (<xref rid="pkae003-B26" ref-type="bibr">26</xref>). In response, a number of strategies were introduced in the United States to reduce opioid prescribing. These included the federal opioid prescription guidelines (<xref rid="pkae003-B27" ref-type="bibr">27</xref>), programs aimed at reducing opioid prescription by clinicians, and state laws restricting opioids (<xref rid="pkae003-B28" ref-type="bibr">28</xref>,<xref rid="pkae003-B29" ref-type="bibr">29</xref>), prescription drug monitoring programs, and health-system-level opioid stewardship programs (<xref rid="pkae003-B30" ref-type="bibr">30-32</xref>)&#8212;all aimed at curbing opioid prescribing. Although these strategies successfully reduced rates of opioid prescribing, adverse repercussions of these programs are not fully understood.</p><p>The Centers for Disease Control and Prevention&#8217;s (CDC&#8217;s) 2016 guidelines included cancer patients &#8220;outside of active cancer treatments&#8221; as part of its scope (<xref rid="pkae003-B27" ref-type="bibr">27</xref>). These guidelines recommended use of nonopioid therapies as first-line treatment for chronic pain patients and encouraged use of short-acting opioids if necessary. However, this distinction overlooked pain trends in cancer survivors (<xref rid="pkae003-B33" ref-type="bibr">33</xref>,<xref rid="pkae003-B34" ref-type="bibr">34</xref>). A longitudinal study on 4903 cancer survivors identified pain as a top-3 symptom affecting quality of life in the first postdiagnosis year. Notably, pain levels were comparable among those who were still receiving active cancer treatments and those who had completed active cancer treatment (<xref rid="pkae003-B33" ref-type="bibr">33</xref>). Although the updated 2022 CDC opioid guidelines excluded cancer patients from its scope altogether (<xref rid="pkae003-B35" ref-type="bibr">35</xref>,<xref rid="pkae003-B36" ref-type="bibr">36</xref>), major changes affecting oncology pain management practices resulting from earlier guidelines appear to be persisting.</p><p>Thus, monitoring ongoing trends in clinical treatment of cancer pain is essential to ensure patients&#8217; symptom management needs are met. However, it is not clear how opioid prescription patterns and social determinants of health (SDoH) variables relate to acute pain intensification (pain flares). Among ambulatory patients with cancer, we investigated (1) patient-level pain flare trajectories and unique longitudinal clusters of daily cancer pain flares and (2) if opioid prescription and SDoH factors predicted experience of high-occurrence pain flares over time.</p><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>This study was based on data from a larger, ongoing prospective observational study (1R01NR017853) to examine long-term relationships among patterns of opioid use, patient-reported outcomes, and health-care use in ambulatory patients with cancer. The data for this analysis were collected between November 2019 and November 2022. A repeated-measures survey was administered at 5 timepoints (ie, T1&#8201;=&#8201;baseline; T2&#8201;=&#8201;1&#8201;month; T3&#8201;=&#8201;2&#8201;months; T4&#8201;=&#8201;3&#8201;months, T5&#8201;=&#8201;5&#8201;months), and daily ecological momentary assessments (mEMA) for pain severity, pain flares, and opioid self-management were collected at each timepoint. In addition, relevant clinical variables were extracted from the review of electronic medical records corresponding to the study timepoints. The study was approved by the University of Pennsylvania&#8217;s Institutional Review Board (IRB protocol #833009). The study followed recommended STROBE guidelines for reporting of observational studies (<xref rid="pkae003-B37" ref-type="bibr">37</xref>).</p></sec><sec><title>Study participants</title><p>Participants were recruited from the outpatient oncology clinics of a large health system in the mid-Atlantic region consisting of 6 hospitals and including an NCI-designated cancer center. Participants were older than 18&#8201;years of age, self-identified as African American or White, had a non-skin malignancy, and were prescribed at least 1 extended release or 2 subsequent immediate-release opioid prescriptions in the past 6 months for ongoing pain. Eligible participants provided at least 10 days&#8217; worth of pain flares data using mEMA, which was considered analytically necessary to estimate pain flares&#8217; trajectories over time. Patients were excluded if they were receiving opioids only for treatment of opioid use disorder or procedural pain, residing in a nursing home or receiving hospice care, or had cognitive deficits or medical conditions that interfered with informed consent.</p></sec><sec><title>Study measures</title><p>The key study outcome was the patient-reported rating of the number of pain flares on daily mEMA assessment collected using a previously validated question: &#8220;How many pain flares or attacks did you have in the past 24&#8201;hours?&#8221; (<xref rid="pkae003-B38" ref-type="bibr">38</xref>). The terminology &#8220;pain flare&#8221; was purposefully chosen, as it aligns with the language commonly used by patients as a lay term for BTP and conveys a distinct intensification of preexisting pain. Ratings ranged from 0 to 10, with 10 meaning 10 or more pain flares. The NCI definition of pain flare was used to offer additional context for respondents, that is, &#8220;A sudden increase in pain that may occur in patients who already have chronic pain from cancer &#8230; Breakthrough pain usually lasts for a short time. During breakthrough pain, the level of pain may be severe but the type of pain and where it is in the body were usually the same as the patient&#8217;s chronic pain&#8221; (<xref rid="pkae003-B39" ref-type="bibr">39</xref>).</p><p>The following validated self-reported measures were administered at survey timepoints to assess for pain severity and function (Brief Pain Inventory Short Form) (<xref rid="pkae003-B40" ref-type="bibr">40</xref>), health-related quality of life (Functional Assessment of Cancer Therapy&#8211;General [FACT-G]) (<xref rid="pkae003-B41" ref-type="bibr">41</xref>), depression (Patient Health Questionnaire) (<xref rid="pkae003-B42" ref-type="bibr">42</xref>,<xref rid="pkae003-B43" ref-type="bibr">43</xref>); opioid misuse (Current Opioid Misuse Measure [COMM]) (<xref rid="pkae003-B44" ref-type="bibr">44</xref>), alcoholism (Cut down, Annoyed, Guilty, Eye-opener [CAGE]) (<xref rid="pkae003-B45" ref-type="bibr">45</xref>,<xref rid="pkae003-B46" ref-type="bibr">46</xref>), and use of complementary and alternative modalities to manage pain on the basis of National Center for Complementary and Integrative Health categories (<xref rid="pkae003-B47" ref-type="bibr">47</xref>). Patient-reported data also included age, sex, race, Hispanic ethnicity, marital status, living status, education, household income, employment status, and health insurance type. In addition, the electronic medical record for each patient was reviewed at baseline and at each study timepoint to assess cancer type, stage and metastatic disease, comorbidities, number, types, frequencies, and doses of unique opioid prescriptions.</p></sec><sec><title>Data analyses</title><sec><title>Participant-level pain flare trajectories</title><p>First, to facilitate understanding of pain flare variability across time, participant-level pain flare trajectories were categorized into 6 types: constant, increasing, decreasing, concave, convex, and oscillating. Next, variability was considered by calculating means and half-widths of error bands for each participant&#8217;s pain flares over 10 equally spaced times. These 20 vectors, comprising 10 mean estimates and 10 half-width estimates, represented trajectories. Trajectories were matched for participants at proportional study times, allowing for different participation times. The 20 vectors were adaptively clustered into trajectory patterns, using a mixture of multivariate normal distributions for each cluster. Clusters had distinct mean and standard deviation vectors, but shared correlation matrices to simplify the model. Likelihoods and likelihood cross-validation scores were computed for clustering alternatives, considering 1-10 clusters using various methods. Clustering options required cluster sizes to be at least 10% of the sample size to avoid sparse clusters. The selected clustering alternative was the one generating the highest likelihood cross-validation&#160;score, determined through analysis (<xref rid="pkae003-B48" ref-type="bibr">48</xref>,<xref rid="pkae003-B49" ref-type="bibr">49</xref>). Subsequent analysis focused on dichotomous indicator of highest pain flare cluster compared with lower pain flare clusters.</p></sec><sec><title>Pain flare clusters</title><p>Proportional odds logistic regression models based on cumulative logits were used to characterize increasing levels of pain flares. Sociodemographic, pain, opioid, and other relevant predictors of pain flares were used to generate individual predictor models for high-occurrence pain flare trajectories. To assess composite predictor effects, the multiple logistic regression model based on all individually significant variables was computed, assessed for multicollinearity using R<sup>2</sup> values, and then adjusted using backward elimination to identify a unique set of predictors of high-occurrence pain flares. Further, participant characteristics between those in the highest identified pain flare cluster and those in the other low-moderate pain flare clusters were compared using 2-sample <italic toggle="yes">t</italic> tests and &#967;<sup>2</sup> tests for continuous and categorical measures, respectively. Statistical analysis was performed using SAS 9.4 for Windows. An alpha level of 0.05 was used for determining statistical significance.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><p>Of the 379 participants in the parent study at the time of this analysis, 317 provided mEMA data for 1-150&#8201;days of study participation. Of these, 270 (82.5%) provided at least 10 pain flare daily measurements (<xref rid="pkae003-T1" ref-type="table">Table&#160;1</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>, available online). The final sample of 270 participants was primarily female (64.8%), and one-third of the participants were African American (32.6%). Breast (20%) and lung (12.2%) were the most common types of cancers, with 45.6% participants diagnosed with either stage III or stage IV cancer. Mean age was 60.9 (SD, 11.23), and participants reported mean pain flares of 3.1 (SD, 3.75). Participants provided a range of 10-255&#8201;days of daily pain flare data. The majority of participants (n&#8201;=&#8201;266, 98.52%) reported at least one pain flare during the observation period. One-third of participants (N&#8201;=&#8201;91, 33.7%) reported at least 1 pain flare on each day of observation. More than half of the participants were prescribed PRN-only opioids (51.7%), and 39.8% were prescribed both ATC + PRN opioids; the remaining 8.6% were prescribed LA/ATC opioids without PRN coverage (<xref rid="pkae003-T2" ref-type="table">Table&#160;2</xref>).</p><table-wrap position="float" id="pkae003-T1" orientation="portrait"><label>Table 1.</label><caption><p>Baseline characteristics of participants and distribution by pain flare clusters</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th colspan="2" rowspan="1">Baseline characteristic</th><th align="center" rowspan="1" colspan="1">Total (N&#8201;=&#8201;270)</th><th align="center" rowspan="1" colspan="1">High pain flares (n&#8201;=&#8201;62)</th><th align="center" rowspan="1" colspan="1">Low-moderate pain flares (n&#8201;=&#8201;208)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age mean (SD)</td><td rowspan="1" colspan="1">Years</td><td rowspan="1" colspan="1">60.9 (11.23)</td><td rowspan="1" colspan="1">60.1 (11.16)</td><td rowspan="1" colspan="1">61.1 (11.27)</td><td rowspan="1" colspan="1">.557</td></tr><tr><td rowspan="1" colspan="1">BHLS score</td><td rowspan="1" colspan="1">Mean (SD)</td><td rowspan="1" colspan="1">12.2 (3.08)</td><td rowspan="1" colspan="1">12.0 (3.11)</td><td rowspan="1" colspan="1">12.3 (3.08)</td><td rowspan="1" colspan="1">.592</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">95 (35.2%)</td><td rowspan="1" colspan="1">22 (35.5%)</td><td rowspan="1" colspan="1">73 (35.1%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">175 (64.8%)</td><td rowspan="1" colspan="1">40 (64.5%)</td><td rowspan="1" colspan="1">135 (64.9%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Race</td><td rowspan="1" colspan="1">African American</td><td rowspan="1" colspan="1">88 (32.6%)</td><td rowspan="1" colspan="1">26 (41.9%)</td><td rowspan="1" colspan="1">62 (29.8%)</td><td rowspan="1" colspan="1">.089</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">182 (67.4%)</td><td rowspan="1" colspan="1">36 (58.1%)</td><td rowspan="1" colspan="1">146 (70.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Ethnicity</td><td rowspan="1" colspan="1">Hispanic or Latino</td><td rowspan="1" colspan="1">5 (1.9%)</td><td rowspan="1" colspan="1">3 (4.8%)</td><td rowspan="1" colspan="1">2 (1.0%)</td><td rowspan="1" colspan="1">.081</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Non-Hispanic or non-Latino</td><td rowspan="1" colspan="1">265 (98.1%)</td><td rowspan="1" colspan="1">59 (95.2%)</td><td rowspan="1" colspan="1">206 (99.0%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Marital status</td><td rowspan="1" colspan="1">Married</td><td rowspan="1" colspan="1">147 (54.4%)</td><td rowspan="1" colspan="1">26 (41.9%)</td><td rowspan="1" colspan="1">121 (58.2%)</td><td rowspan="1" colspan="1">.069</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Separated, divorced, widowed</td><td rowspan="1" colspan="1">65 (24.1%)</td><td rowspan="1" colspan="1">18 (29.0%)</td><td rowspan="1" colspan="1">47 (22.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Never married</td><td rowspan="1" colspan="1">58 (21.5%)</td><td rowspan="1" colspan="1">18 (29.0%)</td><td rowspan="1" colspan="1">40 (19.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Education</td><td rowspan="1" colspan="1">High school (9-12) or less</td><td rowspan="1" colspan="1">109 (40.4%)</td><td rowspan="1" colspan="1">32 (51.6%)</td><td rowspan="1" colspan="1">77 (37.0%)</td><td rowspan="1" colspan="1">.125</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">College/Trade (13-16)</td><td rowspan="1" colspan="1">119 (44.1%)</td><td rowspan="1" colspan="1">23 (37.1%)</td><td rowspan="1" colspan="1">96 (46.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">More than college (&gt;17)</td><td rowspan="1" colspan="1">42 (15.6%)</td><td rowspan="1" colspan="1">7 (11.3%)</td><td rowspan="1" colspan="1">35 (16.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Household income</td><td rowspan="1" colspan="1">&lt;$30&#8202;000</td><td rowspan="1" colspan="1">83 (30.9%)</td><td rowspan="1" colspan="1">30 (48.4%)</td><td rowspan="1" colspan="1">53 (25.6%)</td><td rowspan="1" colspan="1">.004</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">$30&#8202;000-$89&#8202;999</td><td rowspan="1" colspan="1">108 (40.1%)</td><td rowspan="1" colspan="1">20 (32.3%)</td><td rowspan="1" colspan="1">88 (42.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#8805;$90&#8202;000</td><td rowspan="1" colspan="1">78 (29.0%)</td><td rowspan="1" colspan="1">12 (19.4%)</td><td rowspan="1" colspan="1">66 (31.9%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Employment status</td><td rowspan="1" colspan="1">Employed</td><td rowspan="1" colspan="1">57 (21.1%)</td><td rowspan="1" colspan="1">8 (12.9%)</td><td rowspan="1" colspan="1">49 (23.6%)</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Unemployed, disabled</td><td rowspan="1" colspan="1">114 (42.2%)</td><td rowspan="1" colspan="1">39 (62.9%)</td><td rowspan="1" colspan="1">75 (36.1%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Retired</td><td rowspan="1" colspan="1">99 (36.7%)</td><td rowspan="1" colspan="1">15 (24.2%)</td><td rowspan="1" colspan="1">84 (40.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Insurance status</td><td rowspan="1" colspan="1">Private</td><td rowspan="1" colspan="1">103 (38.4%)</td><td rowspan="1" colspan="1">16 (25.8%)</td><td rowspan="1" colspan="1">87 (42.2%)</td><td rowspan="1" colspan="1">.027</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Medicare</td><td rowspan="1" colspan="1">126 (47.0%)</td><td rowspan="1" colspan="1">32 (51.6%)</td><td rowspan="1" colspan="1">94 (45.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Medicaid</td><td rowspan="1" colspan="1">39 (14.6%)</td><td rowspan="1" colspan="1">14 (22.6%)</td><td rowspan="1" colspan="1">25 (12.1%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Cancer type</td><td rowspan="1" colspan="1">Lung</td><td rowspan="1" colspan="1">33 (12.2%)</td><td rowspan="1" colspan="1">8 (12.9%)</td><td rowspan="1" colspan="1">25 (12.0%)</td><td rowspan="1" colspan="1">.910</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Breast</td><td rowspan="1" colspan="1">54 (20.0%)</td><td rowspan="1" colspan="1">12 (19.4%)</td><td rowspan="1" colspan="1">42 (20.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Colon</td><td rowspan="1" colspan="1">13 (4.8%)</td><td rowspan="1" colspan="1">4 (6.5%)</td><td rowspan="1" colspan="1">9 (4.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Prostate</td><td rowspan="1" colspan="1">15 (5.6%)</td><td rowspan="1" colspan="1">4 (6.5%)</td><td rowspan="1" colspan="1">11 (5.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">155 (57.4%)</td><td rowspan="1" colspan="1">34 (54.8%)</td><td rowspan="1" colspan="1">121 (58.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Cancer stage</td><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">82 (30.4%)</td><td rowspan="1" colspan="1">15 (24.2%)</td><td rowspan="1" colspan="1">67 (32.2%)</td><td rowspan="1" colspan="1">.459</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">III/IV</td><td rowspan="1" colspan="1">123 (45.6%)</td><td rowspan="1" colspan="1">32 (51.6%)</td><td rowspan="1" colspan="1">91 (43.8%)</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap position="float" id="pkae003-T2" orientation="portrait"><label>Table 2.</label><caption><p>Pain, opioid, and clinical characteristics by pain flare clusters<sup>a</sup></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="(" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Total (N&#8201;=&#8201;270)</th><th align="center" rowspan="1" colspan="1">High pain flares cluster (n&#8201;=&#8201;62)</th><th align="center" rowspan="1" colspan="1">Low-moderate pain flares cluster (n&#8201;=&#8201;208)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Pain-related variables (mean, SD)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Pain flares</td><td rowspan="1" colspan="1">3.1 (3.75)</td><td rowspan="1" colspan="1">5.5 (5.47)</td><td rowspan="1" colspan="1">2.4 (2.74)</td><td rowspan="1" colspan="1">.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;BPI: Severity</td><td rowspan="1" colspan="1">4.5 (2.03)</td><td rowspan="1" colspan="1">5.5 (2.14)</td><td rowspan="1" colspan="1">4.2 (1.89)</td><td rowspan="1" colspan="1">.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;BPI Worst Pain</td><td rowspan="1" colspan="1">6.2 (2.33)</td><td rowspan="1" colspan="1">7.5 (2.08)</td><td rowspan="1" colspan="1">5.9 (2.28)</td><td rowspan="1" colspan="1">.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;BPI Least Pain</td><td rowspan="1" colspan="1">3.0 (2.35)</td><td rowspan="1" colspan="1">3.9 (2.88)</td><td rowspan="1" colspan="1">2.7 (2.10)</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;BPI: Interference</td><td rowspan="1" colspan="1">4.8 (2.56)</td><td rowspan="1" colspan="1">6.2 (2.26)</td><td rowspan="1" colspan="1">4.4 (2.49)</td><td rowspan="1" colspan="1">.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;BPI: Interference</td><td rowspan="1" colspan="1">4.8 (2.56)</td><td rowspan="1" colspan="1">6.2 (2.26)</td><td rowspan="1" colspan="1">4.4 (2.49)</td><td rowspan="1" colspan="1">.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;NPQ Pain to Touch</td><td rowspan="1" colspan="1">30.6 (33.57)</td><td rowspan="1" colspan="1">44.0 (39.62)</td><td rowspan="1" colspan="1">26.6 (30.52)</td><td rowspan="1" colspan="1">.000</td></tr><tr><td rowspan="1" colspan="1">Opioid management (No. %)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">MME category</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8804;25 MME</td><td rowspan="1" colspan="1">46 (17.0%)</td><td rowspan="1" colspan="1">12 (19.4%)</td><td rowspan="1" colspan="1">34 (16.3%)</td><td rowspan="1" colspan="1">.125</td></tr><tr><td rowspan="1" colspan="1">&#8195;26-50 MME</td><td rowspan="1" colspan="1">71 (26.3%)</td><td rowspan="1" colspan="1">22 (35.5%)</td><td rowspan="1" colspan="1">49 (23.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;51-90 MME</td><td rowspan="1" colspan="1">74 (27.4%)</td><td rowspan="1" colspan="1">11 (17.7%)</td><td rowspan="1" colspan="1">63 (30.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;90+ MME</td><td rowspan="1" colspan="1">79 (29.3%)</td><td rowspan="1" colspan="1">17 (27.4%)</td><td rowspan="1" colspan="1">62 (29.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Opioid prescription</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;PRN only</td><td rowspan="1" colspan="1">139 (51.7%)</td><td rowspan="1" colspan="1">41 (67.2%)</td><td rowspan="1" colspan="1">98 (47.1%)</td><td rowspan="1" colspan="1">.024</td></tr><tr><td rowspan="1" colspan="1">&#8195;Both PRN + LA/ATC</td><td rowspan="1" colspan="1">107 (39.8%)</td><td rowspan="1" colspan="1">17 (27.9%)</td><td rowspan="1" colspan="1">90 (43.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;LA/ATC only</td><td rowspan="1" colspan="1">23 (8.6%)</td><td rowspan="1" colspan="1">3 (4.9%)</td><td rowspan="1" colspan="1">20 (9.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Opioid risks (mean, SD)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;COMM score</td><td rowspan="1" colspan="1">6.6 (5.18)</td><td rowspan="1" colspan="1">8.4 (6.18)</td><td rowspan="1" colspan="1">6.0 (4.72)</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;ORT OUD score</td><td rowspan="1" colspan="1">1.6 (1.58)</td><td rowspan="1" colspan="1">1.7 (1.68)</td><td rowspan="1" colspan="1">1.6 (1.55)</td><td rowspan="1" colspan="1">.585</td></tr><tr><td rowspan="1" colspan="1">&#8195;CAGE score mean</td><td rowspan="1" colspan="1">0.1 (0.49)</td><td rowspan="1" colspan="1">0.2 (0.66)</td><td rowspan="1" colspan="1">0.1 (0.43)</td><td rowspan="1" colspan="1">.477</td></tr><tr><td rowspan="1" colspan="1">Alcohol problems (CAGE) (No. %)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">260 (96.3%)</td><td rowspan="1" colspan="1">59 (95.2%)</td><td rowspan="1" colspan="1">201 (96.6%)</td><td rowspan="1" colspan="1">.701</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">10 (3.7%)</td><td rowspan="1" colspan="1">3 (4.8%)</td><td rowspan="1" colspan="1">7 (3.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Pain self-management</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Cannabis use</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;No cannabis</td><td rowspan="1" colspan="1">173 (64.1%)</td><td rowspan="1" colspan="1">39 (62.9%)</td><td rowspan="1" colspan="1">134 (64.4%)</td><td rowspan="1" colspan="1">.638</td></tr><tr><td rowspan="1" colspan="1">&#8195;Medical</td><td rowspan="1" colspan="1">68 (25.2%)</td><td rowspan="1" colspan="1">14 (22.6%)</td><td rowspan="1" colspan="1">54 (26.0%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Recreational</td><td rowspan="1" colspan="1">20 (7.4%)</td><td rowspan="1" colspan="1">6 (9.7%)</td><td rowspan="1" colspan="1">14 (6.7%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Medical and recreational</td><td rowspan="1" colspan="1">9 (3.3%)</td><td rowspan="1" colspan="1">3 (4.8%)</td><td rowspan="1" colspan="1">6 (2.9%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CBD-alone products</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">226 (83.7%)</td><td rowspan="1" colspan="1">53 (85.5%)</td><td rowspan="1" colspan="1">173 (83.2%)</td><td rowspan="1" colspan="1">.845</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">44 (16.3%)</td><td rowspan="1" colspan="1">9 (14.5%)</td><td rowspan="1" colspan="1">35 (16.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Acupuncture</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">249 (92.6%)</td><td rowspan="1" colspan="1">56 (91.8%)</td><td rowspan="1" colspan="1">193 (92.8%)</td><td rowspan="1" colspan="1">.784</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">20 (7.4%)</td><td rowspan="1" colspan="1">5 (8.2%)</td><td rowspan="1" colspan="1">15 (7.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Cognitive behavioral therapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">261 (97.4%)</td><td rowspan="1" colspan="1">58 (96.7%)</td><td rowspan="1" colspan="1">203 (97.6%)</td><td rowspan="1" colspan="1">.655</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">7 (2.6%)</td><td rowspan="1" colspan="1">2 (3.3%)</td><td rowspan="1" colspan="1">5 (2.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Physical therapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td rowspan="1" colspan="1">74 (27.4%)</td><td rowspan="1" colspan="1">20 (32.3%)</td><td rowspan="1" colspan="1">54 (26.0%)</td><td rowspan="1" colspan="1">.334</td></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td rowspan="1" colspan="1">196 (72.6%)</td><td rowspan="1" colspan="1">42 (67.7%)</td><td rowspan="1" colspan="1">154 (74.0%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PSEQ score</td><td rowspan="1" colspan="1">32.2 (14.36)</td><td rowspan="1" colspan="1">27.8 (15.21)</td><td rowspan="1" colspan="1">33.5 (13.87)</td><td rowspan="1" colspan="1">.006</td></tr><tr><td rowspan="1" colspan="1">Clinical outcomes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Quality of Life (FACT-G)</td><td rowspan="1" colspan="1">67.5 (17.62)</td><td rowspan="1" colspan="1">61.1 (18.50)</td><td rowspan="1" colspan="1">69.4 (16.93)</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Sleep (PSQI Global Score)</td><td rowspan="1" colspan="1">10.6 (3.62)</td><td rowspan="1" colspan="1">10.8 (3.45)</td><td rowspan="1" colspan="1">10.5 (3.68)</td><td rowspan="1" colspan="1">.609</td></tr><tr><td rowspan="1" colspan="1">&#8195;Depression (PHQ-8)</td><td rowspan="1" colspan="1">8.5 (5.23)</td><td rowspan="1" colspan="1">9.8 (5.14)</td><td rowspan="1" colspan="1">8.1 (5.20)</td><td rowspan="1" colspan="1">.023</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p>ATC = around-the-clock; BPI = Brief Pain Inventory; CAGE = Cut down, Annoyed, Guilty, Eye-opener; COMM = Current Opioid Misuse Measure; FACT-G = Functional Assessment of Cancer Therapy&#8212;General; LA = long-acting; MME = morphine milligram equivalent; NPQ = Neuropathic Pain Questionnaire; PHQ-8&#8201;=&#8201;Patient Health Questionnaire-8; PRN = pro re nata, &#8220;as needed&#8221;; PSQI = Pittsburgh Sleep Quality Index Global Score.</p></fn></table-wrap-foot></table-wrap><sec><title>Participant-level pain flares trajectories</title><p>Participant-level trajectories fit 1 of the 6 categories: constant or close to constant, increasing, decreasing, concave, convex, and oscillating (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>, available online). The majority of the participants (95%) demonstrated the 3 trajectories as shown in <xref rid="pkae003-F1" ref-type="fig">Figure&#160;1</xref>.</p><fig position="float" id="pkae003-F1" orientation="portrait"><label>Figure 1.</label><caption><p>Examples of individual-level pain flare trajectories over study participation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pkae003f1.jpg"/></fig><sec><title>Pain flare clusters</title><p>Four pain flare clusters were identified. The mean distribution for these clusters and variability over time are reported in <xref rid="pkae003-F2" ref-type="fig">Figures&#160;2</xref> and <xref rid="pkae003-F3" ref-type="fig">3</xref>, respectively. Combined, these plots indicate that the clusters represent increasing or more problematic levels of pain flares over time. Among the clusters with the highest mean pain flares, mean pain flares were greater than 4 across time (high-occurrence), whereas mean flares were less than 4 among the 3 other clusters (low-moderate occurrence) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>, available online).</p><fig position="float" id="pkae003-F2" orientation="portrait"><label>Figure 2.</label><caption><p>Plot of averages of pain flare means over proportional time during study participation for 4 identified clusters.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pkae003f2.jpg"/></fig><fig position="float" id="pkae003-F3" orientation="portrait"><label>Figure 3.</label><caption><p>Plot of averages of pain flare half-widths over proportional time during study participation for 4 identified clusters.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pkae003f3.jpg"/></fig></sec></sec><sec><title>High-occurrence vs low-moderate occurrence clusters</title><p>Of the sample, 23% of participants were in high-occurrence pain clusters (cluster 4) having a mean of 5.5 (SD, 5.47) pain flares each day vs clusters 1-3 (77%), who had a mean of 2.4 (SD, 2.74) pain flares each day (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.000). In total, 67.2% of patients receiving PRN-only opioids were in the &#8220;high-occurrence pain flare cluster&#8221; vs 27.9% receiving both PRN + ATC opioids (<italic toggle="yes">P</italic>&#8201;=&#8201;.024) (<xref rid="pkae003-T1" ref-type="table">Table&#160;1</xref>).</p><p>Patients in the high-occurrence pain flare cluster (compared with low-moderate occurrence) reported higher levels of worst pain (<italic toggle="yes">P</italic>&#8201;=&#8201;.000), least pain scores (<italic toggle="yes">P</italic>&#8201;=&#8201;.001), and greater pain-related interference (<italic toggle="yes">P</italic>&#8201;=&#8201;.000). Additionally, the Pain to Touch subscale of neuropathic pain was higher for those with high-occurrence flares compared with those with fewer flares (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.000). Patients in the high-occurrence pain cluster also had poorer quality of life (<italic toggle="yes">P</italic>&#8201;=&#8201;.001) and lower self-efficacy in managing pain (<italic toggle="yes">P</italic>&#8201;=&#8201;.006). (<xref rid="pkae003-T2" ref-type="table">Table&#160;2</xref>).</p></sec><sec><title>Predictors of high-occurrence pain flares</title><p>In the individual predictor models, several SDoH variables were significantly associated with high-occurrence pain flares, including income less than $30&#8202;000 compared to those earning more than $90&#8202;000, followed by being unemployed, being African American (compared with White or Caucasian), having a high school education or less, and having Medicaid insurance. Other significant variables included COMM score, baseline inpatient hospital stay duration, quality of life (FACT-G), and being prescribed a PRN-only opioid regimen (when compared with PRN + ATC regimens) (<xref rid="pkae003-T3" ref-type="table">Table&#160;3</xref>).</p><table-wrap position="float" id="pkae003-T3" orientation="portrait"><label>Table 3.</label><caption><p>Predictors of high pain flares cluster<sup>a</sup></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Predictor</th><th rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Individually significant predictors</td></tr><tr><td rowspan="1" colspan="1">&#8195;African Americans</td><td rowspan="1" colspan="1">Whites/Caucasians</td><td rowspan="1" colspan="1">2.04</td><td rowspan="1" colspan="1">1.28-3.24</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;High school or less</td><td rowspan="1" colspan="1">College, trade school, or more than college</td><td rowspan="1" colspan="1">2.17</td><td rowspan="1" colspan="1">1.39-3.39</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Income &lt;$30&#8202;000</td><td rowspan="1" colspan="1">&gt;$90&#8202;000</td><td rowspan="1" colspan="1">3.24</td><td rowspan="1" colspan="1">1.83-5.75</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Unemployed, disabled, other</td><td rowspan="1" colspan="1">Employed</td><td rowspan="1" colspan="1">2.89</td><td rowspan="1" colspan="1">1.61-5.21</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Medicaid insurance</td><td rowspan="1" colspan="1">Private Insurance</td><td rowspan="1" colspan="1">2.65</td><td rowspan="1" colspan="1">1.35-5.19</td><td rowspan="1" colspan="1">.005</td></tr><tr><td rowspan="1" colspan="1">&#8195;Opioid misuse (COMM)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.06</td><td rowspan="1" colspan="1">1.02-1.11</td><td rowspan="1" colspan="1">.006</td></tr><tr><td rowspan="1" colspan="1">&#8195;Quality of life (FACT-G)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">0.98-1.00</td><td rowspan="1" colspan="1">.041</td></tr><tr><td rowspan="1" colspan="1">&#8195;Inpatient long stay (Yes)</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">2.02</td><td rowspan="1" colspan="1">1.13-3.61</td><td rowspan="1" colspan="1">.018</td></tr><tr><td rowspan="1" colspan="1">&#8195;PRN only opioid prescription</td><td rowspan="1" colspan="1">Both PRN + ATC</td><td rowspan="1" colspan="1">1.59</td><td rowspan="1" colspan="1">1.10-2.51</td><td rowspan="1" colspan="1">.046</td></tr><tr><td colspan="5" rowspan="1">Multiple predictor model</td></tr><tr><td rowspan="1" colspan="1">&#8195;High school or less</td><td rowspan="1" colspan="1">College, trade school, or more than college</td><td rowspan="1" colspan="1">2.10</td><td rowspan="1" colspan="1">1.32-3.35</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">&#8195;Unemployed, disabled, other</td><td rowspan="1" colspan="1">Employed or retired</td><td rowspan="1" colspan="1">2.31</td><td rowspan="1" colspan="1">1.45-3.70</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;COMM</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.05</td><td rowspan="1" colspan="1">1.01-1.10</td><td rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">&#8195;Inpatient long stay (Yes)</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">2.06</td><td rowspan="1" colspan="1">1.13-3.77</td><td rowspan="1" colspan="1">0.019</td></tr><tr><td rowspan="1" colspan="1">&#8195;PRN-only opioid prescription</td><td rowspan="1" colspan="1">Both PRN + ATC</td><td rowspan="1" colspan="1">2.02</td><td rowspan="1" colspan="1">1.28-3.20</td><td rowspan="1" colspan="1">0.003</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><label>a</label><p>ATC = around-the-clock; COMM = Current Opioid Misuse Measure; FACT-G = Functional Assessment of Cancer Therapy&#8211;General; PRN = pro re nata, &#8220;as needed.&#8221;</p></fn></table-wrap-foot></table-wrap><p>R<sup>2</sup> values for models of each individually significant predictor as a function of the other individually significant predictors (computed using logistic regression for dichotomous predictors and linear regression for continuous variables) ranged from 3.8% to 30.8%, indicating that multicollinearity was not a problem for the model on the basis of all these predictors. For the backward elimination adjusted multiple predictor model, patients with a high school education or less (odds ratio [OR]&#8201;=&#8201;2.10, 95% confidence interval [CI] = 1.32 to 3.35; <italic toggle="yes">P</italic>&#8201;=&#8201;.002), unemployment (OR&#8201;=&#8201;2.31, 95% CI = 1.45 to 3.70; <italic toggle="yes">P</italic>&#8201;=&#8201;.001), COMM score (OR&#8201;=&#8201;1.05, 95% CI = 1.01 to 1.10; <italic toggle="yes">P</italic>&#8201;=&#8201;.022), an extended EMT inpatient duration (OR&#8201;=&#8201;2.06, 95% CI = 1.13 to 3.77; <italic toggle="yes">P</italic>&#8201;=&#8201;.019), and PRN-only opioid regimen (OR&#8201;=&#8201;2.02, 95% CI = 1.28 to 3.20; <italic toggle="yes">P</italic>&#8201;=&#8201;.003) remained significant predictors of high-occurrence pain flare cluster membership. The strength of PRN-only opioid regimen became stronger in the multiple predictor model controlling for other variables (<xref rid="pkae003-T3" ref-type="table">Table&#160;3</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study is the first to characterize cancer pain flares over an extended observation period in ambulatory patients using a daily ecological survey approach. We identified unique pain flare clusters and reported on social, demographic, and clinical predictors of high-occurrence pain flare clusters offering insights that could potentially inform better clinical patient management approaches.</p><p>The findings underscore the crucial significance of various social determinants, such as an income below $30&#8202;000, unemployment, lower educational attainment, Medicaid insurance, and self-identification as African American, in explaining high-occurrence pain flares on an individual level. In the adjusted model, lower educational attainment and unemployment were significant SDoH factors predicting high-occurrence pain flares.</p><p>Both unemployment and lower educational attainment can significantly contribute to the exacerbation of pain flares. Educational attainment impacts employment disparities by shaping job opportunities, work conditions, income levels, and access to health insurance (<xref rid="pkae003-B50" ref-type="bibr">50</xref>,<xref rid="pkae003-B51" ref-type="bibr">51</xref>). Aside from financial strain, unemployment can disrupt daily routines, social connections, and limit access to pain medications, all of which can, in turn, worsen pain symptoms (<xref rid="pkae003-B20" ref-type="bibr">20</xref>,<xref rid="pkae003-B52" ref-type="bibr">52</xref>). Beyond financial strain and access, well-developed communication models to effectively convey complex medical information to individuals with diverse educational backgrounds are often missing, creating additional pain self-management challenges for patients (<xref rid="pkae003-B53" ref-type="bibr">53</xref>).</p><p>Although not all social determinants retained their significance in the adjusted model, these variables continue to be intricately interwoven in our sociopolitical landscape (<xref rid="pkae003-B54" ref-type="bibr">54</xref>,<xref rid="pkae003-B55" ref-type="bibr">55</xref>). Overall, these findings point to a grave scenario of poor pain care for underserved patients with cancer, who already grapple with complex health and social challenges.</p><p>Aside from social factors, we found that the odds of experiencing higher pain flares were more than doubled for patients prescribed PRN-only opioids and that more than half of the patients in this study were prescribed PRN-only opioids even though oncology cancer pain guidelines recommend the use of ATC opioids in addition to immediate-release opioids at approximately 10% of the daily MME dose for BTP (<xref rid="pkae003-B56" ref-type="bibr">56</xref>). Because of perceived confusion across cancer pain management guidelines (<xref rid="pkae003-B34" ref-type="bibr">34</xref>,<xref rid="pkae003-B57" ref-type="bibr">57</xref>), clinicians and oncologists might have genuine uncertainty about how best to manage cancer pain, especially using opioids. As the ASCO guidelines authors recently concluded, &#8220;Opioids have long been the foundation of cancer pain management, yet serious challenges to their use exist, including a striking lack of research to guide clinical practice in this population&#8221; (<xref rid="pkae003-B56" ref-type="bibr">56</xref>).</p><p>As noted earlier, opioid prescription, especially prescription of long-acting opioids, has declined significantly in the United States, including among oncology practitioners (<xref rid="pkae003-B23" ref-type="bibr">23-25</xref>,<xref rid="pkae003-B58" ref-type="bibr">58</xref>). There are newer concerns that an increased number of cancer patients may be receiving insufficient treatment or remaining untreated for pain (<xref rid="pkae003-B25" ref-type="bibr">25</xref>,<xref rid="pkae003-B58" ref-type="bibr">58</xref>). For example, the majority of patients in our study reported moderate or severe pain intensity, especially those in the high pain flares cluster, but only 28% in the high-occurrence pain cluster were prescribed both ATC/PRN opioids. Attention to this subgroup is important, as there is accumulating evidence that poorly controlled pain increases the risk of suicide (<xref rid="pkae003-B59" ref-type="bibr">59</xref>,<xref rid="pkae003-B60" ref-type="bibr">60</xref>). This scenario is made worse by poor access to nonopioid, nonpharmacological treatments, such as complementary and integrative treatments for pain, especially by SDoH factors such as lack of insurance coverage and significant out-of-pocket costs (<xref rid="pkae003-B61" ref-type="bibr">61</xref>,<xref rid="pkae003-B62" ref-type="bibr">62</xref>).</p><p>Finally, our adjusted findings also point to a very small but significant role of opioid misuse factors in predicting high-occurrence pain flares. However, taken collectively (magnitude of pain in this sample and opioid prescription patterns), this finding might reflect the clinical phenomenon of poorly controlled baseline pain. In contrast to an opioid use disorder, opioid misuse may or may not be related to overuse of opioids (<xref rid="pkae003-B63" ref-type="bibr">63</xref>). Indeed among patients with cancer, underuse of opioids, rather than overuse of opioids, has been found to be the main concern (<xref rid="pkae003-B20" ref-type="bibr">20</xref>,<xref rid="pkae003-B64" ref-type="bibr">64-66</xref>). Underuse of opioids in patients with cancer occurs due to opioid stigma, heightened fears of addiction, and lack of patient education on correct use of opioids (<xref rid="pkae003-B64" ref-type="bibr">64</xref>,<xref rid="pkae003-B65" ref-type="bibr">65</xref>). In fact, a significant number of cancer patients may have considerable gaps in opioid use, which may lead to both opioid safety risks and poor baseline pain control (<xref rid="pkae003-B64" ref-type="bibr">64</xref>,<xref rid="pkae003-B65" ref-type="bibr">65</xref>,<xref rid="pkae003-B67" ref-type="bibr">67</xref>,<xref rid="pkae003-B68" ref-type="bibr">68</xref>). Further studies are needed to understand how opioid prescription patterns may be associated with cancer pain control and trajectories of pain flares to generate an evidence base to inform clinical practice and cancer pain guidelines.</p></sec><sec><title>Limitations</title><p>Investigating pain flare trajectories and predictors was an exploratory aim of our study, and our study sample was not powered for this purpose. Despite this, the findings point to pain flares as a significant clinical phenomenon with important actionable correlates. Because we collected pain flare data as part of daily ecological assessment, we limited the number of daily survey items to manage participant burden. Consequently, we did not collect detailed information on the types of pain flares or their onset, duration, and mitigating factors. Future studies may employ more comprehensive approaches to understanding pain flares, including patient perspectives, as well as their impact on more distal clinical outcomes, such as health-related quality of life and daily function. Although our study controlled for disease stage, our analysis of pain flares may not fully capture the complexity of interactions and variability in pain experiences across different cancer types and stages. We used the stage of disease as a proxy. However, this method may not fully adjust for nuanced differences in pain experiences specific to each type of cancer. These limitations should be considered when our findings are interpreted.</p><p>In this study, we examined the trajectories and clinical and SDoH factors influencing high-occurrence pain flares in ambulatory patients with cancer. Findings showed that PRN-only opioid regimens resulted in 102% higher odds of encountering pain flares compared with ATC opioids. Additionally, SDoH variables were predictors of higher pain flare occurrence. These insights are crucial in the current context where opioid prescriptions are declining and access to nonpharmacological treatments remains limited. The study underscores the pressing need for an evidence-based approach to managing pain flares that considers both prescription patterns and SDoH needs. This could better equip providers and services to mitigate acute pain intensification, including among vulnerable populations.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>pkae003_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pkae003_supplementary_data.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgments</title><p>The funder did not play a role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.</p></ack><sec sec-type="data-availability"><title>Data availability</title><p>Deidentified data for the primary outcome will be made available via a request to the principal investigator with a data use agreement in accordance with the institutional policies.</p></sec><sec><title>Author contributions</title><p>Salimah H. Meghani, PhD, MBE, RN (Conceptualization; Funding acquisition; Methodology; Supervision; Writing&#8212;original draft; Writing&#8212;review &amp; editing), Ryan Quinn, MPH (Data curation; Formal analysis; Methodology; Writing&#8212;review &amp; editing), Andrew Robinson, BA (Data curation; Project administration; Validation; Writing&#8212;review &amp; editing), Jesse Chittams, MA (Data curation; Formal analysis; Methodology; Writing&#8212;review &amp; editing), Neha Vapiwala, MD (Investigation; Writing&#8212;review &amp; editing), Mary Naylor, PhD (Investigation; Writing&#8212;review &amp; editing), Martin Cheatle, PhD (Investigation; Writing&#8212;review &amp; editing), George J Knafl, PhD (Data curation; Formal analysis; Investigation; Methodology; Supervision; Writing&#8212;review &amp; editing).</p></sec><sec><title>Funding</title><p>This study was funded by the National Institutes of Health, National Institute of Nursing Research (R01NR017853 PI: Meghani).</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>The authors have no potential conflicts of interest to disclose. This study was funded by the National Institutes of Health, National Institute of Nursing Research (R01NR017853 PI: Meghani). MC, MN, and NV are the Co-Investigators on the grant. GJK is the named statistician on the grant and received a consultation fee for the data analyses.</p></sec><ref-list id="ref1"><title>References</title><ref id="pkae003-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Snijders</surname><given-names>RAH</given-names></string-name>, <string-name name-style="western"><surname>Brom</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Theunissen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>van den Beuken-van Everdingen</surname><given-names>MHJ.</given-names></string-name></person-group><article-title>Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis</article-title>. <source>Cancers (Basel)</source>. <year>2023</year>;<volume>15</volume>(<issue>3</issue>):591.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15030591</pub-id><pub-id pub-id-type="pmcid">PMC9913127</pub-id><pub-id pub-id-type="pmid">36765547</pub-id></mixed-citation></ref><ref id="pkae003-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van den Beuken-van Everdingen</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Hochstenbach</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Joosten</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Tjan-Heijnen</surname><given-names>VC</given-names></string-name>, <string-name name-style="western"><surname>Janssen</surname><given-names>DJ.</given-names></string-name></person-group><article-title>Update on prevalence of pain in patients with cancer: systematic review and meta-analysis</article-title>. <source>J Pain Symptom Manage</source><italic toggle="yes">.</italic><year>2016</year>;<volume>51</volume>(<issue>6</issue>):<fpage>1070</fpage>-<lpage>1090.e1079</lpage>.<pub-id pub-id-type="pmid">27112310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2015.12.340</pub-id></mixed-citation></ref><ref id="pkae003-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lohre</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Klepstad</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>MI</given-names></string-name></person-group>, <etal>et al</etal>; <collab>European Association for Palliative Care Research N</collab>. <article-title>From &#8220;breakthrough&#8221; to &#8220;episodic&#8221; cancer pain? A European association for palliative care research network expert Delphi survey toward a common terminology and classification of transient cancer pain exacerbations</article-title>. <source>J Pain Symptom Manage</source>. <year>2016</year>;<volume>51</volume>(<issue>6</issue>):<fpage>1013</fpage>-<lpage>1019</lpage>.<pub-id pub-id-type="pmid">26921493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2015.12.329</pub-id></mixed-citation></ref><ref id="pkae003-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeppetella</surname><given-names>G.</given-names></string-name></person-group><article-title>Impact and management of breakthrough pain in cancer</article-title>. <source>Curr Opin Support Palliat Care</source>. <year>2009</year>;<volume>3</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="pmid">19365156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SPC.0b013e3283260658</pub-id></mixed-citation></ref><ref id="pkae003-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davies</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Buchanan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zeppetella</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal><article-title>Breakthrough cancer pain: an observational study of 1000 European oncology patients</article-title>. <source>J Pain Symptom Manage</source>. <year>2013</year>;<volume>46</volume>(<issue>5</issue>):<fpage>619</fpage>-<lpage>628</lpage>.<pub-id pub-id-type="pmid">23523361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2012.12.009</pub-id></mixed-citation></ref><ref id="pkae003-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deandrea</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Corli</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Consonni</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Villani</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Greco</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Apolone</surname><given-names>G.</given-names></string-name></person-group><article-title>Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature</article-title>. <source>J Pain Symptom Manage</source>. <year>2014</year>;<volume>47</volume>(<issue>1</issue>):<fpage>57</fpage>-<lpage>76</lpage>.<pub-id pub-id-type="pmid">23796584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2013.02.015</pub-id></mixed-citation></ref><ref id="pkae003-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Retrospective observational study on the characteristics of pain and associated factors of breakthrough pain in advanced cancer patients</article-title>. <source>Pain Res Manag</source>. <year>2022</year>;<volume>2022</volume>:<fpage>8943292</fpage>.<pub-id pub-id-type="pmid">35463627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/8943292</pub-id><pub-id pub-id-type="pmcid">PMC9023204</pub-id></mixed-citation></ref><ref id="pkae003-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Greco</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Corli</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Montanari</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal>; <collab>Cancer Pain Outcome Research Study Group (CPOR SG) Investigators; Cancer Pain Outcome Research Study Group I</collab>. <article-title>Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the cancer pain outcome research study group</article-title>. <source>Clin J Pain</source>. <year>2011</year>;<volume>27</volume>(<issue>1</issue>):<fpage>9</fpage>-<lpage>18</lpage>.,<pub-id pub-id-type="pmid">20842024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AJP.0b013e3181edc250</pub-id></mixed-citation></ref><ref id="pkae003-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Portenoy</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Payne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jacobsen</surname><given-names>P.</given-names></string-name></person-group><article-title>Breakthrough pain: characteristics and impact in patients with cancer pain</article-title>. <source>Pain</source>. <year>1999</year>;<volume>81</volume>(<issue>1-2</issue>):<fpage>129</fpage>-<lpage>134</lpage>.<pub-id pub-id-type="pmid">10353500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0304-3959(99)00006-8</pub-id></mixed-citation></ref><ref id="pkae003-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brant</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Rodgers</surname><given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Gallagher</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sundaramurthi</surname><given-names>T.</given-names></string-name></person-group><article-title>Breakthrough cancer pain: a systematic review of pharmacologic management</article-title>. <source>Clin J Oncol Nurs</source>. <year>2017</year>;<volume>21</volume>(<issue>suppl 3</issue>):<fpage>71</fpage>-<lpage>80</lpage>.<pub-id pub-id-type="pmid">28524907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1188/17.CJON.S3.71-80</pub-id></mixed-citation></ref><ref id="pkae003-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haugen</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Hjermstad</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Hagen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Caraceni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kaasa</surname><given-names>S</given-names></string-name></person-group>; <collab>European Palliative Care Research Collaborative (EPCRC)</collab>. <article-title>Assessment and classification of cancer breakthrough pain: a systematic literature review</article-title>. <source>Pain</source>. <year>2010</year>;<volume>149</volume>(<issue>3</issue>):<fpage>476</fpage>-<lpage>482</lpage>.,<pub-id pub-id-type="pmid">20236762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2010.02.035</pub-id></mixed-citation></ref><ref id="pkae003-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suresh</surname><given-names>NV</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chorath</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>Clinical practice guidelines in the management of breakthrough cancer pain: a systematic review using the appraisal of guidelines for research and evaluation (agree II) instrument</article-title>. <source>Pain Manag Nurs</source>. <year>2022</year>;<volume>23</volume>(<issue>4</issue>):<fpage>411</fpage>-<lpage>417</lpage>.<pub-id pub-id-type="pmid">35305935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pmn.2022.02.010</pub-id></mixed-citation></ref><ref id="pkae003-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Portenoy</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Hagen</surname><given-names>NA.</given-names></string-name></person-group><article-title>Breakthrough pain: definition and management</article-title>. <source>Oncology (Williston Park)</source>. <year>1989</year>;<volume>3</volume>(<issue>suppl 8</issue>):<fpage>25</fpage>-<lpage>29</lpage>.<pub-id pub-id-type="pmid">2484297</pub-id></mixed-citation></ref><ref id="pkae003-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haq</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>McMahan</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Torres</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Race, pain, and opioids among patients with chronic pain in a safety-net health system</article-title>. <source>Drug Alcohol Depend</source>. <year>2021</year>;<volume>222</volume>:<fpage>108671</fpage>.<pub-id pub-id-type="pmid">33810908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2021.108671</pub-id><pub-id pub-id-type="pmcid">PMC8687128</pub-id></mixed-citation></ref><ref id="pkae003-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Retnam</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Sutton</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Edmonds</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Bandyopadhyay</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sheppard</surname><given-names>VB.</given-names></string-name></person-group><article-title>Racial disparities in opioid prescription and pain management among breast cancer survivors</article-title>. <source>Cancer Med</source>. <year>2023</year>;<volume>12</volume>(<issue>9</issue>):<fpage>10851</fpage>-<lpage>10864</lpage>.<pub-id pub-id-type="pmid">36916310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.5755</pub-id><pub-id pub-id-type="pmcid">PMC10225217</pub-id></mixed-citation></ref><ref id="pkae003-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chittams</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McMenamin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Fudin</surname><given-names>J.</given-names></string-name></person-group><article-title>African Americans with cancer pain are more likely to receive an analgesic with toxic metabolite despite clinical risks: a mediation analysis study</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>25</issue>):<fpage>2773</fpage>-<lpage>2779</lpage>.<pub-id pub-id-type="pmid">25049323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2013.54.7992</pub-id><pub-id pub-id-type="pmcid">PMC4145186</pub-id></mixed-citation></ref><ref id="pkae003-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Quinn</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ashare</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal><article-title>Impact of cannabis use on least pain scores among African American and white patients with cancer pain: a moderation analysis</article-title>. <source>J Pain Res</source>. <year>2021</year>;<volume>14</volume>:<fpage>3493</fpage>-<lpage>3502</lpage>.<pub-id pub-id-type="pmid">34764689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S332447</pub-id><pub-id pub-id-type="pmcid">PMC8577564</pub-id></mixed-citation></ref><ref id="pkae003-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Rosa</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Chittams</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vallerand</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>JJ.</given-names></string-name></person-group><article-title>Both race and insurance type independently predict the selection of oral opioids prescribed to cancer outpatients</article-title>. <source>Pain Manag Nurs</source>. <year>2020</year>;<volume>21</volume>(<issue>1</issue>):<fpage>65</fpage>-<lpage>71</lpage>.<pub-id pub-id-type="pmid">31501079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pmn.2019.07.004</pub-id><pub-id pub-id-type="pmcid">PMC6980435</pub-id></mixed-citation></ref><ref id="pkae003-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yeager</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Rosa</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Belcher</surname><given-names>SM</given-names></string-name></person-group>, <etal>et al</etal><article-title>A qualitative study of the pain experience of black individuals with cancer taking long-acting opioids</article-title>. <source>Cancer Nurs</source>. <year>2023</year>. doi:<pub-id pub-id-type="doi">10.1097/NCC.0000000000001197</pub-id><pub-id pub-id-type="pmcid">PMC10400728</pub-id><pub-id pub-id-type="pmid">36737858</pub-id></mixed-citation></ref><ref id="pkae003-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Chittams</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bruner</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Riegel</surname><given-names>B.</given-names></string-name></person-group><article-title>Adherence to analgesics for cancer pain: a comparative study of African Americans and whites using an electronic monitoring device</article-title>. <source>J Pain</source>. <year>2015</year>;<volume>16</volume>(<issue>9</issue>):<fpage>825</fpage>-<lpage>835</lpage>.<pub-id pub-id-type="pmid">26080042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2015.05.009</pub-id><pub-id pub-id-type="pmcid">PMC4578964</pub-id></mixed-citation></ref><ref id="pkae003-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Canick</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Bhardwaj</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Sociodemographic differences in patient-reported pain and pain management of patients with head and neck cancer in a community oncology setting</article-title>. <source>J Clin Oncol Oncol Pract</source>. <year>2023</year>;<volume>19</volume>(<issue>3</issue>):<fpage>e397</fpage>-<lpage>e406</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/OP.22.00132</pub-id><pub-id pub-id-type="pmcid">PMC10022872</pub-id><pub-id pub-id-type="pmid">36480772</pub-id></mixed-citation></ref><ref id="pkae003-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morden</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Chyn</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Meara</surname><given-names>E.</given-names></string-name></person-group><article-title>Racial inequality in prescription opioid receipt&#8212;role of individual health systems</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>(<issue>4</issue>):<fpage>342</fpage>-<lpage>351</lpage>.<pub-id pub-id-type="pmid">34289277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMsa2034159</pub-id><pub-id pub-id-type="pmcid">PMC8402927</pub-id></mixed-citation></ref><ref id="pkae003-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agarwal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dusetzina</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Royce</surname><given-names>TJ.</given-names></string-name></person-group><article-title>Changes in opioid prescribing patterns among generalists and oncologists for Medicare Part D beneficiaries from 2013 to 2017</article-title>. <source>JAMA Oncol</source>. <year>2020</year>;<volume>6</volume>(<issue>8</issue>):<fpage>1271</fpage>-<lpage>1274</lpage>.<pub-id pub-id-type="pmid">32469405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.2211</pub-id><pub-id pub-id-type="pmcid">PMC7260690</pub-id></mixed-citation></ref><ref id="pkae003-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jairam</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>DX</given-names></string-name>, <string-name name-style="western"><surname>Pasha</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Temporal trends in opioid prescribing patterns among oncologists in the Medicare population</article-title>. <source>J Natl Cancer Inst</source>. <year>2021</year>;<volume>113</volume>(<issue>3</issue>):<fpage>274</fpage>-<lpage>281</lpage>.<pub-id pub-id-type="pmid">32785685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa110</pub-id><pub-id pub-id-type="pmcid">PMC7936059</pub-id></mixed-citation></ref><ref id="pkae003-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Enzinger</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>AA.</given-names></string-name></person-group><article-title>Reduced opioid prescribing by oncologists: progress made, or ground lost?</article-title><source>J Natl Cancer Inst</source><italic toggle="yes">.</italic><year>2021</year>;<volume>113</volume>(<issue>3</issue>):<fpage>225</fpage>-<lpage>226</lpage>.<pub-id pub-id-type="pmid">32785658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djaa112</pub-id><pub-id pub-id-type="pmcid">PMC7936062</pub-id></mixed-citation></ref><ref id="pkae003-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ju</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Man</surname><given-names>KKC</given-names></string-name></person-group>, <etal>et al</etal><article-title>Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study</article-title>. <source>Lancet Public Health</source>. <year>2022</year>;<volume>7</volume>(<issue>4</issue>):<fpage>e335</fpage>-<lpage>e346</lpage>.<pub-id pub-id-type="pmid">35366408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(22)00013-5</pub-id></mixed-citation></ref><ref id="pkae003-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dowell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Haegerich</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Chou</surname><given-names>R.</given-names></string-name></person-group><article-title>CDC guideline for prescribing opioids for chronic pain&#8212;United States, 2016</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>(<issue>15</issue>):<fpage>1624</fpage>-<lpage>1645</lpage>.<pub-id pub-id-type="pmid">26977696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.1464</pub-id><pub-id pub-id-type="pmcid">PMC6390846</pub-id></mixed-citation></ref><ref id="pkae003-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Danielson</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Harle</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Silverman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Blackburn</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Menachemi</surname><given-names>N.</given-names></string-name></person-group><article-title>Assessing variation in state opioid tapering laws: comparing state laws with the CDC guideline</article-title>. <source>Pain Med</source><italic toggle="yes">.</italic><year>2021</year>;<volume>22</volume>(<issue>12</issue>):<fpage>2941</fpage>-<lpage>2949</lpage>.<pub-id pub-id-type="pmid">34196723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pm/pnab208</pub-id></mixed-citation></ref><ref id="pkae003-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seitz</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Janiszewski</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Guy</surname><given-names>GP</given-names><suffix>Jr</suffix></string-name></person-group>, <etal>et al</etal><article-title>Evaluating opioid analgesic prescribing limits: a narrative review</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2022</year>;<volume>31</volume>(<issue>6</issue>):<fpage>605</fpage>-<lpage>613</lpage>.<pub-id pub-id-type="pmid">35247021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.5425</pub-id><pub-id pub-id-type="pmcid">PMC9078148</pub-id></mixed-citation></ref><ref id="pkae003-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shoemaker-Hunt</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Wyant</surname><given-names>BE.</given-names></string-name></person-group><article-title>The effect of opioid stewardship interventions on key outcomes: a systematic review</article-title>. <source>J Patient Saf</source>. <year>2020</year>;<volume>16</volume>(<issue>3S suppl 1</issue>):<fpage>S36</fpage>-<lpage>S41</lpage>.<pub-id pub-id-type="pmid">32809999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PTS.0000000000000710</pub-id><pub-id pub-id-type="pmcid">PMC7447172</pub-id></mixed-citation></ref><ref id="pkae003-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gondora</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Versteeg</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>The role of pharmacists in opioid stewardship: a scoping review</article-title>. <source>Res Social Adm Pharm</source>. <year>2022</year>;<volume>18</volume>(<issue>5</issue>):<fpage>2714</fpage>-<lpage>2747</lpage>.<pub-id pub-id-type="pmid">34261590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sapharm.2021.06.018</pub-id></mixed-citation></ref><ref id="pkae003-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cramer</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Wisler</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gouveia</surname><given-names>CJ.</given-names></string-name></person-group><article-title>Opioid stewardship in otolaryngology: state of the art review</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>2018</year>;<volume>158</volume>(<issue>5</issue>):<fpage>817</fpage>-<lpage>827</lpage>.<pub-id pub-id-type="pmid">29437536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0194599818757999</pub-id></mixed-citation></ref><ref id="pkae003-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Michonski</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Kaw</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cleeland</surname><given-names>CS.</given-names></string-name></person-group><article-title>Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's studies of cancer survivors</article-title>. <source>Cancer</source>. <year>2011</year>;<volume>117</volume>(<issue>12</issue>):<fpage>2779</fpage>-<lpage>2790</lpage>.<pub-id pub-id-type="pmid">21495026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.26146</pub-id><pub-id pub-id-type="pmcid">PMC3143572</pub-id></mixed-citation></ref><ref id="pkae003-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Vapiwala</surname><given-names>N.</given-names></string-name></person-group><article-title>Bridging the critical divide in pain management guidelines from the CDC, NCCN, and ASCO for cancer survivors</article-title>. <source>JAMA Oncol</source>. <year>2018</year>;<volume>4</volume>(<issue>10</issue>):<fpage>1323</fpage>-<lpage>1324</lpage>.<pub-id pub-id-type="pmid">29852051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2018.1574</pub-id></mixed-citation></ref><ref id="pkae003-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dowell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ragan</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Chou</surname><given-names>R.</given-names></string-name></person-group><article-title>CDC clinical practice guideline for prescribing opioids for pain&#8212;United States, 2022</article-title>. <source>MMWR Recomm Rep</source>. <year>2022</year>;<volume>71</volume>(<issue>3</issue>):<fpage>1</fpage>-<lpage>95</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.rr7103a1</pub-id><pub-id pub-id-type="pmcid">PMC9639433</pub-id><pub-id pub-id-type="pmid">36327391</pub-id></mixed-citation></ref><ref id="pkae003-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dowell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ragan</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Chou</surname><given-names>R.</given-names></string-name></person-group><article-title>Prescribing opioids for pain&#8212;the new CDC clinical practice guideline</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>387</volume>(<issue>22</issue>):<fpage>2011</fpage>-<lpage>2013</lpage>.<pub-id pub-id-type="pmid">36326116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp2211040</pub-id><pub-id pub-id-type="pmcid">PMC10977898</pub-id></mixed-citation></ref><ref id="pkae003-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>von Elm</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Egger</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal>; <collab>STROBE Initiative</collab>. <article-title>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>(<issue>9596</issue>):<fpage>1453</fpage>-<lpage>1457</lpage>.<pub-id pub-id-type="pmid">18064739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(07)61602-X</pub-id></mixed-citation></ref><ref id="pkae003-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fortner</surname><given-names>BV</given-names></string-name>, <string-name name-style="western"><surname>Okon</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Portenoy</surname><given-names>RK.</given-names></string-name></person-group><article-title>A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain</article-title>. <source>J Pain</source>. <year>2002</year>;<volume>3</volume>(<issue>1</issue>):<fpage>38</fpage>-<lpage>44</lpage>.<pub-id pub-id-type="pmid">14622852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1054/jpai.2002.27136</pub-id></mixed-citation></ref><ref id="pkae003-B39"><label>39</label><mixed-citation publication-type="other"><collab>National Cancer Institute</collab>. Pain management: breakthrough pain<italic toggle="yes">.</italic><year>2023</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/breakthrough-pain" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-terms/def/breakthrough-pain</ext-link>. Accessed September 18, 2023.</mixed-citation></ref><ref id="pkae003-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cleeland</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname><given-names>KM.</given-names></string-name></person-group><article-title>Pain assessment: global use of the brief pain inventory</article-title>. <source>Ann Acad Med Singap</source>. <year>1994</year>;<volume>23</volume>(<issue>2</issue>):<fpage>129</fpage>-<lpage>138</lpage>.<pub-id pub-id-type="pmid">8080219</pub-id></mixed-citation></ref><ref id="pkae003-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cella</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nowinski</surname><given-names>CJ.</given-names></string-name></person-group><article-title>Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2002</year>;<volume>83</volume>(<issue>12 suppl 2</issue>):<fpage>S10</fpage>-<lpage>S17</lpage>.<pub-id pub-id-type="pmid">12474167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/apmr.2002.36959</pub-id></mixed-citation></ref><ref id="pkae003-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wells</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Horton</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>LeardMann</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Jacobson</surname><given-names>IG</given-names></string-name>, <string-name name-style="western"><surname>Boyko</surname><given-names>EJ.</given-names></string-name></person-group><article-title>A comparison of the prime-MD PHQ-9 AND PHQ-8 in a large military prospective study, the millennium cohort study</article-title>. <source>J Affect Disord</source>. <year>2013</year>;<volume>148</volume>(<issue>1</issue>):<fpage>77</fpage>-<lpage>83</lpage>.<pub-id pub-id-type="pmid">23246365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2012.11.052</pub-id></mixed-citation></ref><ref id="pkae003-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spitzer</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Kroenke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>JB.</given-names></string-name></person-group><article-title>Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire</article-title>. <source>JAMA</source>. <year>1999</year>;<volume>282</volume>(<issue>18</issue>):<fpage>1737</fpage>-<lpage>1744</lpage>.<pub-id pub-id-type="pmid">10568646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.282.18.1737</pub-id></mixed-citation></ref><ref id="pkae003-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Butler</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Budman</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Fernandez</surname><given-names>KC</given-names></string-name></person-group>, <etal>et al</etal><article-title>Development and validation of the current opioid misuse measure</article-title>. <source>Pain</source>. <year>2007</year>;<volume>130</volume>(<issue>1-2</issue>):<fpage>144</fpage>-<lpage>156</lpage>.<pub-id pub-id-type="pmid">17493754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2007.01.014</pub-id><pub-id pub-id-type="pmcid">PMC1950245</pub-id></mixed-citation></ref><ref id="pkae003-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ewing</surname><given-names>JA.</given-names></string-name></person-group><article-title>Detecting alcoholism: the Cage Questionnaire</article-title><source>. JAMA</source>. <year>1984</year>;<volume>252</volume>(<issue>14</issue>):<fpage>1905</fpage>-<lpage>1907</lpage>.<pub-id pub-id-type="pmid">6471323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.252.14.1905</pub-id></mixed-citation></ref><ref id="pkae003-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mayfield</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>McLeod</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>P.</given-names></string-name></person-group><article-title>The Cage questionnaire: validation of a new alcoholism screening instrument</article-title>. <source>Am J Psychiatry</source>. <year>1974</year>;<volume>131</volume>(<issue>10</issue>):<fpage>1121</fpage>-<lpage>1123</lpage>.<pub-id pub-id-type="pmid">4416585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/ajp.131.10.1121</pub-id></mixed-citation></ref><ref id="pkae003-B47"><label>47</label><mixed-citation publication-type="other"><collab>National Center for Complementary and Integrative Health (NCCIH)</collab>. <italic toggle="yes">Types of Complementary Health Approaches.</italic><year>2018</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccih.nih.gov/health/providers/terms-related-to-complementary-and-integrative-health" ext-link-type="uri">https://www.nccih.nih.gov/health/providers/terms-related-to-complementary-and-integrative-health</ext-link>. Accessed June 27, 2018.</mixed-citation></ref><ref id="pkae003-B48"><label>48</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Knafl</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Delucchi</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Bova</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Fennie</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>AB.</given-names></string-name></person-group><part-title>A systematic approach for analyzing electronically monitored adherence data</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Ekwall</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cronquist</surname><given-names>M</given-names></string-name></person-group>, eds. <source>Micro Electro Mechanical Systems (Mems) Technology, Fabrication Processes and Applications</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Nova Science Publishers</publisher-name>; <year>2010</year>:<fpage>1</fpage>-<lpage>66</lpage>.</mixed-citation></ref><ref id="pkae003-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Knafl</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Meghani</surname><given-names>SH.</given-names></string-name></person-group><article-title>Modeling individual patient count/rate data over time with applications to cancer pain flares and cancer pain medication usage</article-title>. <source>Open J Stat</source>. <year>2021</year>;<volume>11</volume>(<issue>5</issue>):<fpage>633</fpage>-<lpage>654</lpage>.<pub-id pub-id-type="pmid">35938069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4236/ojs.2021.115038</pub-id><pub-id pub-id-type="pmcid">PMC9351387</pub-id></mixed-citation></ref><ref id="pkae003-B50"><label>50</label><mixed-citation publication-type="other"><collab>Healthy People 2030</collab>. <italic toggle="yes">Social Determinants of Health.</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://health.gov/healthypeople/priority-areas/social-determinants-health" ext-link-type="uri">https://health.gov/healthypeople/priority-areas/social-determinants-health</ext-link>. Accessed September 18, 2023.</mixed-citation></ref><ref id="pkae003-B51"><label>51</label><mixed-citation publication-type="other"><collab>Healthy People 2030</collab>. <italic toggle="yes">Employment</italic>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries/employment#cit30" ext-link-type="uri">https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries/employment#cit30</ext-link>. Accessed September 23, 2023.</mixed-citation></ref><ref id="pkae003-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baker</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>HO</given-names></string-name>, <string-name name-style="western"><surname>Chatters</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Engel</surname><given-names>IJ.</given-names></string-name></person-group><article-title>The intersection of pain outcomes and social isolation among African Americans</article-title>. <source>J Racial Ethn Health Disparities</source>. <year>2022</year>;<volume>9</volume>(<issue>5</issue>):<fpage>1905</fpage>-<lpage>1911</lpage>.<pub-id pub-id-type="pmid">34506012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40615-021-01128-y</pub-id></mixed-citation></ref><ref id="pkae003-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guimond</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Getachew</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nolan</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Miles Sheffield-Abdullah</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Conklin</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Hirschey</surname><given-names>R.</given-names></string-name></person-group><article-title>Communication between black patients with cancer and their oncology clinicians: exploring factors that influence outcome disparities</article-title>. <source>Oncol Nurs Forum</source>. <year>2022</year>;<volume>49</volume>(<issue>6</issue>):<fpage>509</fpage>-<lpage>524</lpage>.<pub-id pub-id-type="pmid">36413731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1188/22.ONF.509-524</pub-id><pub-id pub-id-type="pmcid">PMC10368517</pub-id></mixed-citation></ref><ref id="pkae003-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Chittams</surname><given-names>J.</given-names></string-name></person-group><article-title>Controlling for socioeconomic status in pain disparities research: all-else-equal analysis when &#8220;all else&#8221; is not equal</article-title>. <source>Pain Med</source><italic toggle="yes">.</italic><year>2015</year>;<volume>16</volume>(<issue>12</issue>):<fpage>2222</fpage>-<lpage>2225</lpage>.<pub-id pub-id-type="pmid">26052869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pme.12829</pub-id></mixed-citation></ref><ref id="pkae003-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bertrand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mullainathan</surname><given-names>S.</given-names></string-name></person-group> Are Emily and Greg more employable than Lakisha and Jamal? A field experiment on labor market discrimination. <italic toggle="yes">Am&#160;Econ&#160;Rev</italic>. 2004;<volume>94</volume>(<issue>4</issue>):<fpage>991</fpage>-<lpage>1013</lpage>.</mixed-citation></ref><ref id="pkae003-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paice</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bohlke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Barton</surname><given-names>D</given-names></string-name></person-group>, <etal>et al</etal><article-title>Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline</article-title>. <source>J Clin Oncol</source>. <year>2023</year>;<volume>41</volume>(<issue>4</issue>):<fpage>914</fpage>-<lpage>930</lpage>.<pub-id pub-id-type="pmid">36469839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.02198</pub-id></mixed-citation></ref><ref id="pkae003-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schatz</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Oliver</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Swarm</surname><given-names>RA</given-names></string-name></person-group>, <etal>et al</etal><article-title>Bridging the gap among clinical practice guidelines for pain management in cancer and sickle cell disease</article-title>. <source>J Natl Compr Canc Netw</source>. <year>2020</year>;<volume>18</volume>(<issue>4</issue>):<fpage>392</fpage>-<lpage>399</lpage>.<pub-id pub-id-type="pmid">32259777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2019.7379</pub-id><pub-id pub-id-type="pmcid">PMC9764961</pub-id></mixed-citation></ref><ref id="pkae003-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Paice</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Portenoy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bruera</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Reid</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></string-name></person-group><article-title>Prescription opioids dispensed to patients with cancer with bone metastasis: 2011-2017</article-title>. <source>Oncologist</source>. <year>2021</year>;<volume>26</volume>(<issue>10</issue>):<fpage>e1890</fpage>-<lpage>e1892</lpage>.<pub-id pub-id-type="pmid">34227175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/onco.13898</pub-id><pub-id pub-id-type="pmcid">PMC8488796</pub-id></mixed-citation></ref><ref id="pkae003-B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ashrafioun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kane</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bishop</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Britton</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Pigeon</surname><given-names>WR.</given-names></string-name></person-group><article-title>The association of pain intensity and suicide attempts among patients initiating pain specialty services</article-title>. <source>J Pain</source>. <year>2019</year>;<volume>20</volume>(<issue>7</issue>):<fpage>852</fpage>-<lpage>859</lpage>.<pub-id pub-id-type="pmid">30690167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2019.01.012</pub-id></mixed-citation></ref><ref id="pkae003-B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ilgen</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Zivin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Austin</surname><given-names>KL</given-names></string-name></person-group>, <etal>et al</etal><article-title>Severe pain predicts greater likelihood of subsequent suicide</article-title>. <source>Suicide Life Threat Behav</source>. <year>2010</year>;<volume>40</volume>(<issue>6</issue>):<fpage>597</fpage>-<lpage>608</lpage>.<pub-id pub-id-type="pmid">21198328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1521/suli.2010.40.6.597</pub-id></mixed-citation></ref><ref id="pkae003-B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ludwick</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Corey</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Meghani</surname><given-names>S.</given-names></string-name></person-group><article-title>Racial and socioeconomic factors associated with the use of complementary and alternative modalities for pain in cancer outpatients: an integrative review</article-title>. <source>Pain Manag Nurs</source>. <year>2020</year>;<volume>21</volume>(<issue>2</issue>):<fpage>142</fpage>-<lpage>150</lpage>.<pub-id pub-id-type="pmid">31928745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pmn.2019.08.005</pub-id></mixed-citation></ref><ref id="pkae003-B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liou</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Ashare</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Worster</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>SIO-ASCO guideline on integrative medicine for cancer pain management: implications for racial and ethnic pain disparities</article-title>. <source>JNCI Cancer Spectr</source>. <year>2023</year>;<volume>7</volume>(<issue>4</issue>):pkad042.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncics/pkad042</pub-id><pub-id pub-id-type="pmcid">PMC10336300</pub-id><pub-id pub-id-type="pmid">37307074</pub-id></mixed-citation></ref><ref id="pkae003-B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klimas</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gorfinkel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fairbairn</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal><article-title>Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: a systematic review</article-title>. <source>JAMA Netw Open</source>. <year>2019</year>;<volume>2</volume>(<issue>5</issue>):<fpage>e193365</fpage>.<pub-id pub-id-type="pmid">31050783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2019.3365</pub-id><pub-id pub-id-type="pmcid">PMC6503484</pub-id></mixed-citation></ref><ref id="pkae003-B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Persico</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Fudin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Knafl</surname><given-names>GJ.</given-names></string-name></person-group><article-title>Gaps in the use of long-acting opioids within intervals of consecutive days among cancer outpatients using electronic pill caps</article-title>. <source>Pain Med</source><italic toggle="yes">.</italic><year>2021</year>;<volume>22</volume>(<issue>3</issue>):<fpage>687</fpage>-<lpage>693</lpage>.<pub-id pub-id-type="pmid">32935134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pm/pnaa273</pub-id><pub-id pub-id-type="pmcid">PMC7971460</pub-id></mixed-citation></ref><ref id="pkae003-B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Wool</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yeager</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Barg</surname><given-names>FK.</given-names></string-name></person-group><article-title>When patients take charge of opioids: self-management concerns and practices among cancer outpatients in the context of opioid crisis</article-title>. <source>J Pain Symptom Manage</source>. <year>2020</year>;<volume>59</volume>(<issue>3</issue>):<fpage>618</fpage>-<lpage>625</lpage>.<pub-id pub-id-type="pmid">31711967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2019.10.029</pub-id></mixed-citation></ref><ref id="pkae003-B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yeager</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Factors related to adherence to opioids in Black patients with cancer pain</article-title>. <source>J Pain Symptom Manage</source>. <year>2019</year>;<volume>57</volume>(<issue>1</issue>):<fpage>28</fpage>-<lpage>36</lpage>.<pub-id pub-id-type="pmid">30316809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2018.10.491</pub-id><pub-id pub-id-type="pmcid">PMC6310640</pub-id></mixed-citation></ref><ref id="pkae003-B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Knafl</surname><given-names>GJ.</given-names></string-name></person-group><article-title>Patterns of analgesic adherence predict health care utilization among outpatients with cancer pain</article-title>. <source>Patient Prefer Adherence</source><italic toggle="yes">.</italic><year>2016</year>;<volume>10</volume>:<fpage>81</fpage>-<lpage>98</lpage>.<pub-id pub-id-type="pmid">26869772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/PPA.S93726</pub-id><pub-id pub-id-type="pmcid">PMC4734825</pub-id></mixed-citation></ref><ref id="pkae003-B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meghani</surname><given-names>SH.</given-names></string-name></person-group><article-title>Editorial: extended-release, long-acting opioid self-management patterns may pose safety risks in ambulatory persons with cancer pain</article-title>. <source>Emerg Cancer Care</source><italic toggle="yes">.</italic><year>2023</year>;<volume>2</volume>(4). doi:<pub-id pub-id-type="doi">10.1186/s44201-022-00016-3</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>